Form 4: Impact Biomedical Inc. Sees Significant Share Sales by Director and 10% Owner
SEC Form 4
Director and 10% owner Chan Heng Fai Ambrose, along with related entities Alset International Ltd. and Alset Inc., executed multiple sales of Impact Biomedical Inc. common stock between April 2 and April 4, 2025.
Summary
- This Form 4 filing details the sale of Impact Biomedical Inc. (IBO) common stock by Chan Heng Fai Ambrose, a director and 10% owner, and related entities Alset International Ltd. and Alset Inc.
- Between April 2 and April 4, 2025, Alset International Ltd. sold 502,349 shares in multiple transactions at weighted average prices of $0.581, $0.674 and $0.673.
- Alset Inc. sold 734,058 shares on April 2 and 3, 2025, at weighted average prices of $0.583 and $0.579 respectively.
- Global Biomedical Pte. Ltd. sold 453,286 shares on April 3 and 4, 2025, at weighted average prices of $0.779 and $0.96 respectively.
- After these transactions, Mr. Chan may be deemed the beneficial owner of 351,555 shares of common stock held by Alset International Limited.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the significant share sales by a director and related entities, which could indicate a lack of confidence in the company's future.
Negatives
- A director and 10% owner, along with related entities, significantly reduced their holdings in Impact Biomedical Inc.
Risks
- Continued selling pressure from major shareholders could negatively impact the stock price.
- The reasons behind the share sales are not disclosed, creating uncertainty for investors.
Industry Context
Share sales by significant shareholders are common, but the market often interprets them as a lack of confidence in the company's future prospects. It's important to consider the context of these sales within the broader industry and the company's specific situation.
Comparison to Industry Standards
- It's difficult to compare these transactions to industry standards without knowing the specific reasons for the sales.
- However, large sales by insiders often raise concerns among investors, especially if the company is not performing well or if there are no clear positive catalysts on the horizon.
- Comparable companies might include other small-cap biomedical firms where insider selling has occurred, and the subsequent impact on their stock prices could be analyzed.
Stakeholder Impact
- Shareholders may experience a decline in stock value due to the selling pressure.
- Employee morale could be affected by the perceived lack of confidence from major shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/02/2025 | Alset International Limited sold 300,000 shares at a weighted average price of $0.581. |
| 04/02/2025 | Alset International Limited sold 200,000 shares at a weighted average price of $0.674. |
| 04/02/2025 | Alset International Limited sold 2,349 shares at a weighted average price of $0.673. |
| 04/02/2025 | Alset Inc. sold 382,427 shares at a weighted average price of $0.583. |
| 04/03/2025 | Alset Inc. sold 351,631 shares at a weighted average price of $0.579. |
| 04/03/2025 | Global Biomedical Pte. Ltd. sold 273,286 shares at a weighted average price of $0.779. |
| 04/04/2025 | Global Biomedical Pte. Ltd. sold 180,000 shares at a weighted average price of $0.96. |
| 04/04/2025 | Date of signatures for the Form 4 filing. |
Keywords
Impact Biomedical Inc., IBO, Chan Heng Fai Ambrose, Alset International Ltd., Alset Inc., Global Biomedical Pte. Ltd., share sales, Form 4, beneficial ownership, director, 10% owner
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.